Use of Intrapyloric Botulinum Injections in Children

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04250844

Enrollment

100

Registered

2020-01-31

Start date

2020-03-10

Completion date

2027-05-01

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Feeding Disorders, Gastroparesis, Vomiting

Keywords

Botulinum Toxin

Brief summary

This study aims to evaluate the effect of intrapyloric botulinum toxin in children with feeding disorders.

Detailed description

Chronic vomiting and feeding difficulties are common in young children and have a negative physical and psychosocial impact for patients and families. Currently there is no straightforward treatment algorithm for these issues, and management often involves multiple medication trials and procedures. Intrapyloric botulinum toxin injection has been proposed as a treatment for nausea and vomiting in adults, but there is minimal prior research on use in children and no prior research on use in children with feeding disorders. The aims of this study are: (1) to determine the efficacy of intrapyloric botulinum toxin injection for reducing gastrointestinal symptoms in children, (2) to determine the efficacy of intrapyloric botulinum injections for improving feeding outcomes in children, and (3) to define predictors of response to intrapyloric botulinum toxin injection.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Days to 18 Years

Inclusion criteria

* Patients with chronic nausea, vomiting, or feeding intolerance undergoing upper endoscopy with or without intrapyloric botulinum injections. * Age between 30 days and 18 years.

Exclusion criteria

* Significant uncontrolled inflammation on upper or lower endoscopy * Known inflammatory bowel disease * Uncontrolled thyroid disease * Current opioid use

Design outcomes

Primary

Measure	Time frame	Description
Degree of improvement in quality of life	4 weeks	Quality of life will be measured with the Pediatric Quality of Life Inventory (PedsQL). This is composed of 23 items comprising 4 dimensions: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. Each item is answered using a 3-point scale: 0 (Not at all), 2 (Sometimes), 4 (A lot). Scores range 0 to 100, with lower scores indicating worse quality of life. The outcome will be assessed by calculating the change in score from baseline to 4 weeks.

Secondary

Measure	Time frame	Description
Degree of symptomatic improvement	4 weeks	Symptoms will be measured with the Gastroparesis Cardinal Symptom Index (GCSI). The GCSI is based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). A six-point Likert response scale, ranging from 0 (none) to 5 (very severe) is used to rate severity of each symptom. Scores range from 0 to 45, with higher scores indicating worse symptoms. This outcome will be assess by calculating the change in score from baseline to 4 weeks.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRachel Rosen, MD, MPH

Boston Children's Hospital

Outcome results